Blog

  • BHP Secures $4.3 Billion in Landmark Silver Streaming Agreement Linked to Antamina

    BHP Secures $4.3 Billion in Landmark Silver Streaming Agreement Linked to Antamina

    BHP (LSE:BHP) has struck a long-term silver streaming deal with Wheaton Precious Metals tied to its 33.75% stake in the Antamina copper and zinc operation in Peru. The transaction, supported by firm silver market dynamics, is described as the largest streaming agreement ever completed based on upfront payment.

    Under the terms, BHP will receive an immediate cash payment of US$4.3 billion, alongside additional proceeds equivalent to 20% of prevailing spot silver prices upon delivery. In exchange, Wheaton will receive silver credits initially equal to 33.75% of Antamina’s output attributable to BHP. That share will reduce to 22.5% after a cumulative 100 million ounces of silver have been delivered over the life of the mine.

    BHP clarified that the agreement does not alter its shareholder rights or operational responsibilities at Antamina, nor does it affect existing commercial contracts. The miner will continue to maintain full exposure to copper, zinc and lead production, effectively monetising silver — which it considers a secondary by-product — without impacting its core commodity mix.

    Management positioned the transaction as part of a broader capital allocation strategy aimed at recycling value from non-core streams into higher-return growth initiatives and shareholder distributions. Combined with a recently announced infrastructure-related transaction, the company expects to generate more than US$6 billion in additional liquidity, reinforcing balance sheet flexibility and supporting long-term returns.

    The streaming arrangement is set to take effect from 1 April 2026, with closing anticipated around that date, subject to standard corporate conditions. No regulatory approvals are required. BHP added that the structure is not expected to increase reported debt, allowing it to enhance liquidity while preserving balance sheet strength.

    More about BHP Group Limited

    BHP Group Limited is a globally diversified mining and resources company headquartered in Australia. Its portfolio includes iron ore, copper, metallurgical and energy coal, and other base metals. The company focuses on large, long-life assets that underpin industrial development and support growing demand linked to global infrastructure and the energy transition.

  • GSK Wins EU Clearance for First Twice-Yearly Biologic in Severe Asthma

    GSK Wins EU Clearance for First Twice-Yearly Biologic in Severe Asthma

    GSK (LSE:GSK) has received approval from the European Commission for Exdensur (depemokimab), marking the first ultra-long-acting biologic authorized in the European Union for severe asthma driven by type 2 inflammation. The therapy is also cleared as an add-on treatment for severe chronic rhinosinusitis with nasal polyps. Backed by data from four Phase III studies demonstrating durable efficacy and a favorable safety profile with dosing just twice per year, the decision bolsters GSK’s respiratory portfolio and introduces a differentiated option that could reshape care standards for patients whose disease remains poorly controlled.

    Clinical results underpinning the approval showed sustained symptom control and reduced exacerbations across both indications, highlighting the potential of depemokimab to address unmet needs in type 2 inflammatory disease. The extended dosing schedule may improve adherence and reduce treatment burden compared with more frequent biologic regimens. Meanwhile, the asset continues to be evaluated in additional late-stage trials, supporting potential expansion into other type 2 inflammatory conditions.

    GSK’s broader investment case remains centered on solid profitability and strengthening operational performance. Management’s guidance for 2026 reflects confidence in continued momentum across key franchises, including respiratory and vaccines. Shares appear reasonably valued and offer a modest dividend yield, though technical indicators suggest overbought conditions in the near term. Investors are also monitoring balance-sheet discipline and the consistency of earnings delivery.

    More about GSK

    GSK is a global biopharmaceutical leader specializing in respiratory and inflammatory diseases. Its portfolio spans vaccines, targeted biologics and inhaled therapies. The company’s strategy is focused on advancing respiratory medicine by addressing underlying disease pathways and slowing progression in asthma, chronic obstructive pulmonary disease (COPD), and rare respiratory disorders.

  • A key week for the world?

    A key week for the world?

    Geopolitical tensions seem to have cooled somewhat in recent weeks: the U.S. president is no longer talking about possible operations against Mexico or Colombia, and with Iran, diplomacy seems to have taken precedence. No wonder optimism in gold has faded somewhat, and oil prices have pulled back.

    That said, this could simply be the calm before the storm.

    When it comes to Tehran, although a new round of nuclear talks with the U.S. is expected this week, it is hard to see Iran agreeing to demands such as exporting all of its uranium stockpiles or dismantling its enrichment infrastructure, and renewed domestic protests could also serve as a pretext for action.

    If the U.S. ultimately launches an attack on Iran, the fact that it takes place over the weekend while markets are closed will likely not prevent a risk-off reaction. It would need to be swift, like the one in Venezuela, but that seems unlikely given reports that the U.S. military is preparing for sustained, weeks-long operations.

    In such a scenario, oil prices could spike sharply as traders price in the threat to supplies — especially if the Strait of Hormuz were closed, given the region’s outsized role in global energy flows. This kind of risk premium has supported oil moves recently.

    If the worst were to happen and Iran retaliated by closing the Strait of Hormuz, panic selling could affect a market already under pressure from AI-related concerns. In that scenario, virtually all assets, including silver and gold, could come under pressure — though silver recent price action shows how volatile it has become. Incidentally, cryptocurrencies could be the hardest hit…

    As for the conflict in Ukraine, another round of negotiations is scheduled for February 17 and 18. The fact that talks are continuing is encouraging, but key territorial issues remain unresolved. That makes the prospect of lasting peace in the short term seem quite distant, which is perhaps only good news for defense contractors.

    Thus, even with U.S. markets closed today for Presidents’ Day and China celebrating the Lunar New Year, it is unlikely to be a quiet week. Even if geopolitics remain calm, the minutes from the latest Fed meeting, December PCE data, GDP figures, and weekly jobless claims could further sour sentiment.

  • FTSE 100 opens higher as investors await key UK data; SkinBio tumbles

    FTSE 100 opens higher as investors await key UK data; SkinBio tumbles

    UK equities began the week on a firmer footing Monday as investors positioned ahead of a packed economic schedule. Employment figures are due on Tuesday, followed by inflation data on Wednesday — both seen as potentially influential for the Bank of England’s interest rate decision next month.

    By 1029 GMT, the FTSE 100 was up 0.1%, while sterling edged 0.01% lower against the dollar to 1.3647 in GBP/USD trading. Germany’s DAX was little changed and France’s CAC 40 gained 0.3%.

    UK market movers

    Shares of Barratt Redrow PLC (LSE:BTRW) dropped more than 2% after Deutsche Bank lowered its profit projections and cut its price target by 15%, pointing to weakening market conditions and rising fire-safety remediation expenses.

    Analyst Chris Millington reduced the target price to 454 pence from 536 pence but kept a “buy” recommendation on the stock, which last closed at 388.90 pence. The bank trimmed its underlying pre-tax profit forecasts by 9% for fiscal 2026, 6% for FY27, and 7% for FY28.

    Elsewhere, SkinBioTherapeutics PLC (LSE:SBTX) slumped over 37% after announcing an internal probe into former CEO Stuart Ashman over allegations of material financial misrepresentation. The issue will require a 17% reduction in reported 2025 revenue.

    The skincare-focused group said it will reverse £770,000 in royalty income, a move expected to significantly widen operating losses and push fiscal 2026 performance well below market expectations. Management noted that information received late on February 13 raised “significant doubt” about the legitimacy of the royalty revenue.

    Optima Health PLC (LSE:OPT) declined 4.8% after confirming it had agreed to acquire PAM Healthcare Limited for around £100 million. The deal will be funded through £70 million in new borrowing facilities from HSBC and Barclays, alongside a £30 million bridge loan from Deacon Street Partners Limited, controlled by major shareholder Lord Ashcroft.

    Meanwhile, Schroders PLC (LSE:SDR) was cut to “sector perform” by RBC Capital Markets, which argued that limited upside remains for the asset manager’s shares following Nuveen’s approach. RBC lifted its price target to 610 pence to reflect the cash terms outlined in the 612 pence-per-share offer.

    Economic and political backdrop

    On the housing front, asking prices in the UK were largely flat in February after a record jump in January, according to property portal Rightmove. The average price for newly listed homes slipped by £12 to £368,019, following a 2.8% surge the previous month. Even so, prices are still 2.8% higher than in December, marking the strongest start to a year since 2020.

    In political news, the BBC reported that the UK government is considering accelerating plans to raise defense spending to 3% of GDP. Britain had previously pledged to increase annual defense outlays to 2.5% of economic output by 2027, with a goal of reaching 3% after the 2029 general election.

  • NatWest shares advance after UBS lifts profit outlook

    NatWest shares advance after UBS lifts profit outlook

    Shares of NatWest Group PLC (LSE:NWG) gained 4.6% on Monday after UBS increased its earnings projections for the UK lender, citing robust fourth-quarter performance and stronger capital generation.

    The Swiss bank reiterated its “buy” recommendation and kept its 780 pence price target unchanged, implying potential total returns of around 40%. UBS raised its diluted earnings per share estimates by 5% for 2026, 4% for 2027, and 3% for 2028.

    UBS said NatWest’s fourth-quarter pre-tax profit — excluding notable items and litigation costs — came in 7% ahead of market consensus. Net interest income surpassed expectations by 3%, while operating expenses matched forecasts. Loan impairments were 30% better than anticipated, totaling 13 basis points of loans.

    The broker pointed to “strong” operating momentum, noting expansion in both lending and deposits, as well as an 8 basis point rise in net interest margin compared with the market’s expectation of just a 2 basis point increase.

    NatWest’s common equity tier 1 (CET1) ratio stood at 14.0%, 30 basis points above consensus estimates. That figure reflects the £750 million share buyback announced in connection with the Evelyn Partners transaction.

    Looking ahead, UBS said the bank’s 2026 guidance is broadly in line with current market forecasts, while its newly introduced 2028 targets indicate potential upside of 2–3% relative to consensus and appear achievable.

    Those medium-term goals include a return on tangible equity above 18%, compound annual growth in customer assets and liabilities of more than 4%, a cost-to-income ratio below 45%, and an intention to operate with a CET1 ratio of approximately 13.0%.

  • Rosebank Industries shares slip amid $3.05 billion US acquisition talks

    Rosebank Industries shares slip amid $3.05 billion US acquisition talks

    Rosebank Industries (LSE:ROSE) said it is in advanced negotiations to purchase two U.S.-based companies currently owned by private equity firms, in a deal that carries a headline enterprise value of roughly $3.05 billion.

    The company’s shares declined 2.5% following the announcement.

    According to a company statement, the proposed acquisition would be financed through a mix of new borrowing facilities and an equity raise of approximately £1.9 billion.

    Rosebank did not disclose the identities of the businesses involved or provide a timetable for when the transaction might be finalized.

  • Optima Health shares slide after £100 million PAM takeover agreement

    Optima Health shares slide after £100 million PAM takeover agreement

    Shares of Optima Health (LSE:OPT) dropped 4.8% on Monday after the UK-based provider of technology-enabled corporate health and wellbeing services revealed a deal to purchase PAM Healthcare Limited for roughly £100 million.

    The transaction remains subject to approval under Ireland’s Foreign Direct Investment rules. To fund the purchase, Optima has secured £70 million in new borrowing facilities from HSBC and Barclays, alongside a £30 million bridge loan from Deacon Street Partners Limited, which is controlled by major shareholder Lord Ashcroft.

    The company plans to refinance the bridge facility through a fully underwritten £35 million open offer priced at 175 pence per share — a 17.8% discount to the February 13 closing price. The equity raise is expected to proceed after the acquisition is finalized.

    Management said the deal should enhance adjusted earnings per share beginning in the first full financial year after completion, with EPS accretion projected to exceed 25% by the end of year three. On an unaudited pro forma basis, the combined group is expected to generate more than £26 million in underlying adjusted EBITDA before accounting for synergies.

    “This transformational acquisition underscores our intent in delivering our stated strategic objectives and cements Optima’s position in its attractive and growing market,” said Jonathan Thomas, Chief Executive Officer of Optima Health.

    Founded in 2004, PAM reported unaudited revenue of about £66.6 million for the year ended December 31, 2025, alongside adjusted EBITDA of £8.2 million. The business serves more than 1.5 million employees and works with over 1,500 organizations.

    Following the acquisition, Optima is set to become the clear market leader, with an estimated 15% pro forma market share. The transaction also advances the company toward its longer-term goal of reaching a 25% share of the market. Management expects annual revenue and cost synergies to surpass £5 million once the integration process is complete.

  • Oil holds steady as U.S.–Iran diplomacy offsets OPEC+ supply expectations

    Oil holds steady as U.S.–Iran diplomacy offsets OPEC+ supply expectations

    Crude prices traded in a narrow range on Monday as investors weighed the prospects of renewed U.S.–Iran nuclear negotiations against the likelihood that OPEC+ will move ahead with plans to increase output.

    As of 09:10 GMT, Brent crude was down 18 cents, or 0.3%, at $67.52 per barrel, while U.S. West Texas Intermediate (WTI) slipped 17 cents to $62.72 per barrel.

    Market participation was limited, with financial centers in China, South Korea and Taiwan closed for Lunar New Year, alongside the Presidents Day holiday in the United States.

    Both benchmarks ended last week lower, with Brent easing roughly 0.5% and WTI shedding about 1%, after U.S. President Donald Trump said Washington could potentially reach an agreement with Tehran within a month.

    Washington and Tehran are scheduled to meet again in Geneva on Tuesday for a second round of discussions focused on Iran’s nuclear program and preventing further military escalation.

    An Iranian diplomat was quoted Sunday as saying Tehran is pursuing a deal with the United States that would bring mutual economic benefits, including cooperation in energy and mining investment as well as aircraft purchases.

    Meanwhile, U.S. officials told Reuters that a second aircraft carrier has been deployed to the region and contingency plans are in place for an extended military operation should talks collapse. Iran’s Revolutionary Guards have warned that any strike on Iranian territory could prompt retaliatory action against U.S. military installations.

    “An escalation in tensions with Iran could push Brent toward $80 per barrel. A de-escalation would likely send it back toward $60 per barrel,” SEB analysts said in a research note.

    Although geopolitical risks have provided some underlying support to prices, expectations that the Organization of the Petroleum Exporting Countries and its allies — known collectively as OPEC+ — may restart production increases from April are capping gains. According to Reuters, the group is leaning toward that decision at its March 1 meeting after a three-month pause in supply adjustments.

  • Gold dips and silver weakens as investors reassess U.S. rate path

    Gold dips and silver weakens as investors reassess U.S. rate path

    Gold prices moved modestly lower on Monday, with silver also under pressure, as markets continued to evaluate the trajectory of U.S. interest rates following the latest inflation readings.

    As of 04:25 ET (09:25 GMT), spot gold declined 0.6% to $5,015.40 per ounce, while April gold futures slipped 0.2% to $5,035.25 per ounce.

    Spot silver dropped 0.9% to $77.230 per ounce, and platinum fell 1% to $2,057.10 per ounce.

    Precious metals have seen pronounced volatility over the past two weeks, with sharp intraday swings, and both gold and silver remain well below their late-January highs.

    Trading volumes were muted, with financial markets in China, South Korea, and the United States closed for the session.

    Rate uncertainty keeps metals choppy

    Gold and silver held onto part of last week’s advances, supported by bargain-hunting and a softer U.S. dollar. Rising geopolitical tensions between the U.S. and Iran also contributed to safe-haven demand.

    Even so, both metals continue to trade beneath their late-January peaks and have experienced erratic price movements as investors grapple with uncertainty over the Federal Reserve’s next moves.

    The late-January downturn in gold followed U.S. President Donald Trump’s nomination of Kevin Warsh to replace Jerome Powell as Fed Chair when Powell’s term ends in May.

    Warsh has been perceived as less supportive of aggressive monetary easing, prompting concerns that U.S. financial conditions may remain relatively restrictive in the coming years.

    “The market’s attention is gradually shifting to the potential impact of tariffs, which has yet to fully emerge in economic and inflation data, and doubts remain around future Fed credibility. Such a backdrop will intensify investors’ appetite for real assets like gold,” ANZ analysts said in a note, adding that their longer-term outlook for gold remains broadly constructive.

    Focus turns to Fed minutes and inflation data

    Investors are now awaiting further signals on the U.S. economic outlook, starting with the release of minutes from the Federal Reserve’s January meeting on Wednesday.

    The minutes are expected to offer deeper insight into policymakers’ thinking on interest rates, particularly as markets weigh the possibility of a leadership transition at the central bank.

    Later this week, December’s personal consumption expenditures (PCE) price index — the Fed’s preferred inflation measure — will be published and is likely to influence expectations for the longer-term rate outlook.

    Additional U.S. economic releases scheduled for the week include trade data and industrial production figures.

  • Bitcoin retreats below $69,000 as crypto slump deepens into fourth week

    Bitcoin retreats below $69,000 as crypto slump deepens into fourth week

    Bitcoin (COIN:BTCUSD) moved lower on Monday, adding to a prolonged downturn that has now stretched into a fourth straight week, as persistent uncertainty over U.S. interest rate policy continued to weigh on demand for high-risk assets.

    The leading cryptocurrency slipped after briefly reclaiming the $70,000 level over the weekend. By 00:58 ET, Bitcoin was down 2.7% at $68,409.7.

    Strategy says balance sheet resilient even in sharp downturn

    Strategy (NASDAQ:MSTR) — the largest corporate owner of Bitcoin — said Sunday it remains confident in its ability to service its debt even under a severe price correction.

    In a social media update, the company stated it can “withstand a drawdown in $BTC price to $8K and still have sufficient assets to fully cover our debt.”

    Strategy currently holds 714,644 Bitcoin, financed through a mix of equity issuance and long-term borrowing. Led by outspoken Bitcoin supporter Michael Saylor, the company has continued accumulating the cryptocurrency despite the recent pullback.

    Bitcoin has now surrendered roughly half of its value since reaching a record peak near $126,000 in October. The token has been at the center of broader selling pressure in speculative markets, as shifting expectations around Federal Reserve policy have prompted investors to dial back risk exposure.

    The sustained slide has fueled speculation that Strategy could eventually face pressure to offload part of its holdings to meet liabilities — a scenario Saylor has repeatedly dismissed.

    Earlier this month, Strategy reported a $12.4 billion loss for the December quarter, sharply wider than the $670.8 million loss posted a year earlier. Outside of its substantial Bitcoin position, the company generates relatively modest operating income.

    Altcoins mirror Bitcoin weakness

    The wider crypto market also trended lower, tracking Bitcoin’s ongoing retreat.

    Ether, the second-largest cryptocurrency, fell 6.1% to $1,958.63, while XRP dropped 7.7% to $1.4575.

    BNB declined about 4%, with Solana and Cardano losing 5.4% and 6.2%, respectively.

    Among meme tokens, Dogecoin slumped 11.4%, while $TRUMP shed 2.4%.

    Sentiment across digital assets has remained fragile since October, with both retail and institutional inflows slowing significantly. At the same time, a rally in gold prices and stronger interest in physical safe-haven assets have diverted capital away from cryptocurrencies.